MRI-guided Neuronavigation
Conducted with MRI-guided neuronavigation and comprehensive neuropsychological evaluations
Transcranial Magnetic Stimulation (TMS) is gaining momentum as a non-invasive, drug-free option for supporting individuals with autism spectrum disorder (ASD). At Palmier TMS, we believe in transparency and informed care, which is why we’ve compiled the latest clinical research for families and patients seeking answers.
Below, you'll find highlights from key clinical trials, systematic reviews, and expert insights that illustrate the growing body of evidence supporting TMS as a viable intervention for autism symptoms.
A comprehensive 2024 meta-analysis reviewed 17 peer-reviewed studies exploring TMS in children and adults with ASD. These included both randomized controlled trials (RCTs) and open-label studies.
“TMS has positive effects on stereotypical behavior, repetitive behavior, verbal and social aspects of ASD, leading to overall improvement across all scale scores post-intervention.”
— TMS Institute Research Summary
As the largest TMS study for autism to date, this multisite RCT investigates a 4-week course of iTBS targeting the right temporoparietal junction (rTPJ)—a brain region central to social cognition.
Conducted with MRI-guided neuronavigation and comprehensive neuropsychological evaluations
Aims to assess whether TMS can become the first biomedical treatment specifically for social communication deficits in ASD
Results are pending, but early indicators suggest high potential for this protocol’s use in clinical practice
Leading researchers in neuroscience have voiced optimism about TMS for ASD:
A renowned autism researcher, notes that TMS has been linked to gains in cognitive function and better behavioral outcomes in ASD.
A landmark 2016 review already suggested TMS as a "transformative" approach—one that’s now being validated by current, larger-scale studies.
2024 Systematic Review [1,2,3]
Multisite RCT (2024) [4]
Yale Trial [5]
Deep rTMS Trial [6]
17 studies, including RCTs and open-label trials
Largest ongoing study using iTBS
Double-blind, randomized
Targeted to dorsomedial prefrontal cortex
Reductions in repetitive behaviors; improvements in social communication and neuroconnectivity
Aims to establish TMS as a biomedical treatment for social deficits
Uses EEG/eye-tracking to measure TMS effectiveness on social brain areas
Focused on social relating; results pending
2024 Systematic Review [1,2,3]
Multisite RCT (2024) [4]
Yale Trial [5]
Deep rTMS Trial [6]
17 studies, including RCTs and open-label trials
Largest ongoing study using iTBS
Double-blind, randomized
Targeted to dorsomedial prefrontal cortex
Reductions in repetitive behaviors; improvements in social communication and neuroconnectivity
Aims to establish TMS as a biomedical treatment for social deficits
Uses EEG/eye-tracking to measure TMS effectiveness on social brain areas
Focused on social relating; results pending
The most encouraging data to date suggest that TMS—especially when guided by EEG and tailored to the individual brain—can lead to meaningful improvements in ASD symptoms. These include enhanced social communication, fewer repetitive behaviors, and better emotional regulation. Results are further supported by neuroimaging and electrophysiological changes that reflect real shifts in brain function.
While TMS is not yet FDA-approved for autism, clinical use is growing as more providers—including Palmier TMS—adopt evidence-based protocols supported by science. Additional large-scale studies are in progress, and the momentum behind this treatment continues to build.
📚 References & External Resources